<DOC>
	<DOCNO>NCT02128074</DOCNO>
	<brief_summary>The objective pilot study evaluate efficacy safety KRX-0502 , administer without food , treat iron deficiency anemia subject stage 3 5 non-dialysis dependent chronic kidney disease ( NDD-CKD ) .</brief_summary>
	<brief_title>A Pilot Study KRX-0502 ( Ferric Citrate , Administered Without Food , Treating Iron-deficiency Anemia</brief_title>
	<detailed_description>Previous clinical trial test KRX-0502 administer food , dialysis-dependent NDD-CKD patient . This clinical trial evaluate safety efficacy KRX-0502 treating iron deficiency anemia anemic , stage III V NDD-CKD patient new dose regimen ( without food ) .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Males nonlactating female negative serum pregnancy test ( female childbearing potential ) Screening Age &gt; 18 year Serum ferritin &lt; 300 ng/mL TSAT &lt; 25 % Screening Hemoglobin ≥9.0 g/dL ≤11.5 g/dL Screening eGFR &lt; 60 mL/min Screening use 4variable Modification Diet Renal Disease ( MDRD ) equation Subjects receive phosphate binder medication ( ) , within 4 week prior , screen Symptomatic gastrointestinal bleeding , inflammatory bowel disease , inflammatory bowel syndrome and/or Crohn 's Disease within 24 week prior \ Screening Evidence acute kidney injury requirement dialysis within 8 week prior Screening Kidney transplant anticipate start dialysis expect within 16 week Screening History hemochromatosis IV iron administer within 4 week prior Screening ErythropoiesisStimulating Agent ( ESA ) administer within 4 week prior Screening Blood transfusion within 4 week prior Screening Receipt investigational drug within 4 week prior Screening Cause anemia iron deficiency chronic kidney disease History malignancy last five year Active drug alcohol dependence abuse ( exclude tobacco use ) within 12 month prior Screening Any known allergy iron product Previous intolerance oral ferric citrate Psychiatric disorder interfere subject 's ability comply study protocol Planned surgery hospitalization trial Any medical condition , opinion PI , render subject unable unlikely complete trial would interfere optimal participation trial produce significant risk subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>